JPMorgan analyst Tessa Romero lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $31 from $33 and keeps an Overweight rating on the shares. The firm updated the company’s model post earnings.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights
- ACADIA Pharmaceuticals: Strong Growth Prospects and Strategic Positioning Justify Buy Rating
- ACADIA Pharmaceuticals: Hold Rating Amid Stable U.S. Performance and Growth Potential
- ACADIA Pharmaceuticals: Hold Rating Amid Growth Prospects and Uncertainties